Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis

Hannah Rosenblum, Ahmad Masri, David L. Narotsky, Jeff Goldsmith, Nadira Hamid, Rebecca T. Hahn, Susheel Kodali, Torsten Vahl, Tamim Nazif, Omar K. Khalique, Sabahat Bokhari, Prem Soman, João L. Cavalcante, Mathew S. Maurer, Adam Castaño

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Aims: Advances in diagnostic imaging have increased the recognition of coexisting transthyretin cardiac amyloidosis (ATTR-CA) and severe aortic stenosis (AS), with a reported prevalence between 8–16%. In this prospective study, we aimed to evaluate the implications of ATTR-CA on outcomes after transcatheter aortic valve replacement (TAVR). Methods and results: At two academic centres, we screened patients with severe AS undergoing TAVR for ATTR-CA. Using Kaplan–Meier analysis, we compared survival free from death and a combined endpoint of death and first heart failure hospitalization between patients with and without ATTR-CA. Cox proportional-hazards models were used to determine the association of ATTR-CA with these endpoints. The rate of heart failure hospitalization was compared amongst those with and without ATTR-CA. Overall, 204 patients (83 years, 65% male, Society of Thoracic Surgeons score 6.6%, 72% New York Heart Association class III/IV) were included, 27 (13%) with ATTR-CA. Over a median follow-up of 2.04 years, there was no difference in mortality (log rank, P = 0.99) or the combined endpoint (log rank, P = 0.79) between patients with and without ATTR-CA. In Cox proportional-hazards models, the presence of ATTR-CA was not associated with death. However, patients with ATTR-CA had increased rates of heart failure hospitalization at 1 year (0.372 vs. 0.114 events/person-year, P < 0.004) and 3 years (0.199 vs. 0.111 events/person-year, P = 0.087) following TAVR. Conclusion: In moderate-risk patients with severe AS undergoing TAVR, there was a 13% prevalence of ATTR-CA, which did not affect mortality. The observed increase in heart failure hospitalization following TAVR in those with ATTR-CA suggests the consequences of the underlying infiltrative myopathy.

Original languageEnglish (US)
Pages (from-to)250-258
Number of pages9
JournalEuropean Journal of Heart Failure
Issue number2
StatePublished - Feb 2021


  • Cardiac amyloidosis
  • Severe aortic stenosis
  • Transcatheter aortic valve replacement
  • Transthyretin cardiac amyloidosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this